Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-Month results from a randomized controlled study-Comment

Affiliations

¹ Ophthalmology Department, Affiliated Hospital of Medical School, Ningbo University, Ningbo, People's Republic of China.
² Nottingham Clinical Trials Unit, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

Comment

Jin Cao et al. Clin Exp Ophthalmol. 2019 Jul.

. 2019 Jul;47(5):684-685.

doi: 10.1111/ceo.13505. Epub 2019 Apr 15.

¹ Ophthalmology Department, Affiliated Hospital of Medical School, Ningbo University, Ningbo, People's Republic of China.
² Nottingham Clinical Trials Unit, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

No abstract available

Comment in

Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-Month results from a randomized controlled study-Response.
Li S, Ding X, Zhang J, Lu L. Li S, et al. Clin Exp Ophthalmol. 2019 Jul;47(5):685-686. doi: 10.1111/ceo.13507. Epub 2019 Apr 15. Clin Exp Ophthalmol. 2019. PMID: 30938055 No abstract available.
Ophthalmology Letterbox.
Smith JR. Smith JR. Clin Exp Ophthalmol. 2021 Apr;49(3):225-227. doi: 10.1111/ceo.13908. Epub 2021 Mar 9. Clin Exp Ophthalmol. 2021. PMID: 33686745 No abstract available.

Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study.
Li S, Ding X, Sun L, Zhao X, Zhang A, Lyu C, Liu B, Zhang J, Jin C, Lu L. Li S, et al. Clin Exp Ophthalmol. 2019 Mar;47(2):250-258. doi: 10.1111/ceo.13424. Epub 2018 Nov 22. Clin Exp Ophthalmol. 2019. PMID: 30345611 Clinical Trial.